Buspirone treatment of anxiety associated with pharyngeal dysphagia in a four-year-old.

Abstract

Buspirone is a nonbenzodiazepine anxiolytic that has been effective in uncontrolled trials for treating childhood anxiety disorders. A 4-year-old boy with a history of laryngomalacia (congenital structural abnormality with airway collapse and obstruction on inhalation), pharyngeal dysphagia (difficulty in swallowing), poor weight gain, delayed self-feeding skills, and anxiety symptoms is described. An open trial of buspirone, increased gradually to 12.5 mg daily in divided doses over a period of 22 weeks, was associated with decreased anxiety, improved self-feeding skills, and weight gain. Based on parental reports, buspirone appeared to decrease separation and social anxiety, as well as anxiety associated with eating. Drug discontinuation was associated with symptom relapse, whereas drug readministration lead to the same clinical benefits that had been observed previously. The medication was well tolerated, and its benefits have persisted for over 1 year. No new recommendations can be made regarding the use of buspirone in preschool children or in the treatment of anxious behaviors adversely affecting medical conditions in children and adolescents.

• Authors: G L Hanna, E L Feibusch, K J Albright
• Journal: Journal of child and adolescent psychopharmacology (J Child Adolesc Psychopharmacol) Vol. 7 Issue 2 Pg. 137-43 ( 1997) ISSN: 1044-5463 [Print] United States
• PMID: 9334898 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Anxiety Agents
• Buspirone

Topics

• Anti-Anxiety Agents (therapeutic use)
• Anxiety Disorders (drug therapy, etiology)
• Buspirone (therapeutic use)
• Child, Preschool
• Deglutition Disorders (complications)
• Humans
• Male